Abstract
To evaluate the safety and efficacy of vardenafil in primary care, we undertook a post-marketing surveillance study in 384 men with erectile dysfunction (ED), enrolled by 22 family physicians in Korea, from July 2004 to August 2005. Of the 384 patients enrolled, 343 (89.3%) returned for efficacy assessment and safety evaluation. Among the latter, 279 patients (81.3%) reported that their erectile function improved, 292 (92.1%) showed enhanced IIEF (International Index of Erectile Function)-5 scores and 265 (77.9%) responded that they were ‘very satisfied’ or ‘satisfied’ with vardenafil treatment. The most frequent reason for patient satisfaction with vardenafil was erectile potency (62.4%), followed by safety (42.4%), rapid onset (35.3%), adequate duration of efficacy (28.5%) and easy administration (25.9%). A total of 23 adverse events were observed in 18 patients, with the most frequent being hot flushes (3.2%), followed by headache (1.2%), nasal congestion (0.6%), color vision disturbance (0.3%), dizziness (0.3%), dry mouth (0.3%), dyspepsia (0.3%), nausea (0.3%) and diarrhea (0.3%). Only one patient discontinued vardenafil as a direct result of an adverse event. These results suggest that vardenafil prescribed by primary care physicians improved erectile function and was well tolerated by patients with ED.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.
Ansong KS, Lewis C, Jenkins P, Bell J . Epidemiology of erectile dysfunction: a community-based study in rural New York State. Ann Epidemiol 2000; 10: 293–296.
Chew KK, Earle CM, Stuckey BGA, Jamrozik K, Keogh EJ . Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41–45.
Cho BL, Kim YS, Choi YS, Hong MH, Seo HG, Lee SY et al. Prevalence and risk factors for erectile dysfunction in primary care: results of a Korean study. Int J Impot Res 2003; 15: 323–328.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.
Ahn TY, Lee DS, Kang WC, Hong JH, Kim YS . Validation of an abridged Korean version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Korean J Urol 2001; 42: 535–540.
Sunwoo S, Kim YS, Cho BL, Cheon KS, Seo HG, Rho MK et al. Post-marketing surveillance study of the efficacy and safety of sildenafil prescribed in primary care to erectile dysfunction patients. Int J Impot Res 2005; 17: 71–75.
Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC . Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541–1547.
Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763–771.
Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H . The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004; 45: 634–641.
Potempa AJ, Ulbrich E, Bernard I, Beneke M . Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. Eur Urol 2004; 46: 73–79.
Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR et al. Efficacy and treatment satisfaction with on-demand tadalafil (cialis) in men with erectile dysfunction. Eur Urol 2004; 46: 362–369.
Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–199.
Yoon CJ, Lee SH, Moon KH, Yoo ES, Park JS, Lee KS et al. The analysis of preference for three PDE-5 inhibitors. Korean J Androl 2005; 23: 116–121.
Hackett GI . Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005; 7: 57–65.
Hedelin H, Ströberg P . Treatment for erectile dysfunction based on patient-reported outcome. Drugs 2005; 65: 2245–2251.
Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006–2012.
Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005; 47: 612–621.
Van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M . Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856–864.
Gil A, Martinez E, Oyaguez I, Palacios G, Rejas J . Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–347.
Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–1336.
Acknowledgements
This study is part of a re-examination study of vardenafil, which is supported by a grant from Bayer Korea.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, C., Kim, Y., Sunwoo, S. et al. Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. Int J Impot Res 19, 393–397 (2007). https://doi.org/10.1038/sj.ijir.3901544
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901544
Keywords
This article is cited by
-
Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review
International Journal of Retina and Vitreous (2020)